Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: A review

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 5, 2012, Pages 504-509

  Collier, Andrew ^a   Ghosh, Sujoy ^a   McGlynn, Brian ^a   Hollins, Graham ^a  

^a AYR HOSPITAL   (United Kingdom)

Author keywords

androgen deprivation therapy; cardiovascular disease; metabolic syndrome; prostate cancer; type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANDROSTANOLONE; ANTIANDROGEN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; INSULIN SENSITIZING AGENT; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ABDOMINAL FAT; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTERIAL STIFFNESS; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ELECTRON THERAPY; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORCHIECTOMY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 84866734902     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318201a406     Document Type: Review

References (71)

1. CancerStats Key Facts on Prostate Cancer. Cancer Research UK.http://info.cancerreseachuk.org/cancerstats/types/prostate/?a=5441 (last accessed 09/06/2010).
2. Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst. 1993;85:979-987.
3. Nobes JP, Langley SE, Laing RW. Metabolic syndrome and prostate cancer: a review. Clin Oncol (R Coll Radiol). 2009;21: 183-191.
4. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-A new worldwide definition. Lancet. 2005;366:1059-1062.
5. World Health Organisation. Definition, Diagnosis and Classification of Diabetes and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva (Switzerland): Department of Noncommunicable Disease Surveillance; 1999.
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
7. Huggins C, Hodges CV. Studies on prostatic cancer: I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168:9-12.
8. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 1967;124:1011-1017.
9. Albertsen P. Androgen deprivation in prostate cancer-step by step. N Engl J Med. 2009;360:2572-2574.
10. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4:579-594.
11. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flumatide in prostatic carcinoma. N Eng J Med. 1989;321:419-424. [Erratum N Eng J Med. 1989;321:1420].
12. Pilepich MV, Winter K, John MJ, et al. Phase 111 radiation therapy group (RTOG) trial 86-10 of androgen deprivation therapy adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252.
13. Bolla M, van Tienhoven G, de Reijke TM, et al EORTC Radiation Oncology and Genito-Urinary Tract Cancer Groups. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years AADT-Results of the randomised EORTC phase III trial 22961. J Clin Oncol. 2007;25:5014.
14. D'Amico AV, Denham JW, Bolla M, et al. Short-vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer. 2007;109:2004-2010.
15. Henderson A, Langley SE, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol). 2003;15:318-321.
16. Khaksar SJ, Langley SE, Lovell D, et al. Interstitial low dose rate brachytherapy for prostate cancer-a focus on intermediate-and high-risk disease. Clin Oncol (R Coll Radiol). 2006;18: 513-518.
17. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15:1013-1021.
18. Souhami L, Bae K, Pilepich M, et al. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol. 2009;27:2137-2143.
19. Zumoff B, Strain GW, Miller LK, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71:929-931.
20. Kapoor D, Malkin CJ, Channer KS, et al. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxford). 2005;63:239-250.
21. Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84:3673-3680.
22. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27: 1036-1041.
23. Simon D, Preziosi P, Barrett-Connor E, et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia. 1992;35:173-177.
24. Phillips GB, Jing TY, Resnik LM, et al. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertension. 1993;11:699-702.
25. Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000;23:490-494.
26. Oh JY, Barrett-Connor E, Wedick NM, et al. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002;25: 55-60.
27. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5462-5468.
28. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289:2122-2125.
29. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90:2636-2641.
30. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand. 1992;146:505-510.
31. Simon D, Charles MA, Lahlou N, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care. 2001;24:2149-2151.
32. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. European Journal of Medicine. 1992;1:329-336.
33. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89: 3313-3318.
34. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogo-nadal men with type 2 diabetes. J Clinical Endocrinol. 2006;154: 899-906.
35. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1-7.
36. Corrales JJ, Burgo RM, Garca-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism. 2004;53:666-672.
37. Basu R, Dalla Man C, Campioni M, et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care. 2007;30: 1972-1978.
38. Yeap BB, Almeida OP, Hyde Z, et al. Healthier lifestyle predicts higher circulating testosterone in older men. Clin Endocrinol. 2009:70;455-463.
39. Barry MJ, Delorenzo MA, Walker-Corkery ES, et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006;98:973-978.
40. Basaria S, Lieb J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxford). 2002;56:779-786.
41. Smith MR. Changes in body composition during combined androgen blockade for prostate cancer. Clin Prostate Cancer. 2003;2:18-21.
42. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305-1308.
43. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261-4267.
44. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (London). 2003;104:195-201.
45. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term Androgen-deprivation therapy. J Clin Oncol. 2006;24:3979-3983.
46. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456.
47. Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology. 2007;70:1104-1108.
48. Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007;100:1060-1065.
49. Mcleod DG, Iversen P, See WA, et al, Casodex early prostate cancer trialists' group. Bicalutamide 150mg plus standard versus standard care alone for early prostate cancer. BJU Int. 2006;97: 247-225, 446.
50. Tasi HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516-1524.
51. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493-1500.
52. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25: 2420-2425.
53. Beyer DC, McKeough T, Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:1299-1305.
54. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160-1167.
55. Mulnier HE, Seaman HE, Raleigh VS, et al. Mortality in people with type 2 diabetes in the UK. Diabet Med. 2006;23:516-521.
56. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia. 2009;52:1699-1708.
57. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology. 2007;132:2208-2225.
58. Hsu IR, Kim SP, Kabir M, et al. Metabolic syndrome, hyperinsulinaemia, and cancer. Am J Clin Nutr. 2007;86: 867S-771S.
59. Kim JJ, Accili D. Signaling through IGF-1 and insulin receptors: where is the specificity? Growth Horm IGF Res. 2002;12: 84-90.
60. Frasca F, Pandini G, Scalia P et al. Insulin receptor isoform A, a newly recognised, high affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19: 3278-3288.
61. Venkateswaran V, Haddad AQ, Fleshner NE et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 2007;99: 1793-1800.
62. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006;164:1094-1102.
63. Laukkanen JA, Laaksonen DE, Niskanen L, et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev. 2004;13:1646-1650.
64. Yip J, Mattock MB, Morocutti A, et al. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet. 1993;342:883-887.
65. Deckert T, Feldt-rasmussen B, Borch-Johnsen K, et al. Albumi-nuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219-226.
66. Williams B, Poulter NR, Brown MJ, et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Human Hypertension. 2004;18:139-185.
67. Patel A. Effects of a fixed combination of Perindopril and Indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840.
68. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med. 2000;342:145-153.
69. Hypertension. Management of hypertension in adults in primary care. NICE clinical guideline 34. June 2006. National institute for Health and Clinical Excellence. Available from http://www. nice.org.uk (Accessed: Jan 2010).
70. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
71. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.